3-(3-硝基苯基)-1-丙醇 | 63307-44-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(3-硝基苯基)-1-丙醇
• 英文名称: 3-(3-nitrophenyl)-1-propanol
• 英文别名: 3-(3-nitrophenyl)propan-1-ol；3-(3-nitrophenyl)propanol
• CAS: 63307-44-8
• 化学式: C₉H₁₁NO₃
• mdl: MFCD09028719
• 分子量: 181.191
• InChiKey: ULRDXMHMSLAYDJ-UHFFFAOYSA-N

物化性质

• 沸点：
  340.3±17.0 °C(Predicted)
• 密度：
  1.223±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  66
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2906299090

反应信息

• 作为反应物：
  描述：

  3-(3-硝基苯基)-1-丙醇 在 吡啶 、 氯化亚砜 作用下， 以 苯 为溶剂， 反应 1.0h， 以87%的产率得到3-(3-nitrophenyl)-1-chloropropane
  参考文献：
  名称：

  Polyiodinated Triglyceride Analogs as Potential Computed Tomography Imaging Agents for the Liver

  摘要：

  A series of glyceryl 2-oleoyl 1,3-bis[omega-(3-amino-2,4,6-triiodophenyl]) alkanoates was synthesized, radioiodinated with iodine-125, emulsified, and evaluated for their ability to selectively localize in the liver for potential use as hepatographic agents in computed tomography. All seven analogs displayed rapid liver uptake wherein between 65 and 78% of the injected dose accumulated in the liver by 30 min. Liver values ranged from 46 to 93% 3 h after injection which corresponded to liver to blood ratios ranging from 21 to 450. Moreover, subsequent elimination of radioactivity from the liver was nearly linear with respect to alkyl chain length. Analogs with longer alkyl chain length were eliminated from the liver more rapidly than their shorter chain counterparts. Because of their biochemical similarities to naturally occurring triglycerides, these novel analogs may prove useful not only for high-resolution anatomic imaging of focal liver lesions, but also for evaluating a variety of diffuse diseases known to affect hepatic function and biochemistry.

  DOI：

  10.1021/jm00004a010
• 作为产物：
  描述：

  3-(3-nitrophenyl)acrylic acid methyl ester 在 锂硼氢 、 正癸烯 作用下， 以 四氢呋喃 为溶剂， 反应 18.0h， 以71%的产率得到3-(3-硝基苯基)-1-丙醇
  参考文献：
  名称：

  对-叠氮基苯基-2-苯基链烷酸乙酯分子内环化合成四氢萘木质素酯及其对人肿瘤细胞系生长抑制的评价

  摘要：

  通过带有末端对-叠氮基苯基的2-苯基戊酸/ 2-苯基丁酸酸酯的氮离子的分子内环化作用可直接获得四氢萘木脂酸酯。所述p -azidophenyl取代丁酸乙酯导致乙基spirodienone羧酸盐，而其同系物，得到戊4-（4-氨基苯基）以良好收率-1,2,3,4-四氢化萘-1-羧酸叔丁酯。与此相反，米-叠氮基苯基取代的酯遭受三氟甲烷磺酸的芳族亲核加成。X射线晶体学明确地确定了最终产物的结构，并进行了密度泛函理论研究以合理化环化结果。评价了反应中间体和终产物抑制MCF-7（乳腺癌），NCI-H460（肺癌），SF-268（CNS癌症）和UACC-62（黑素瘤）细胞系体外生长的能力。 。用的spirodienone羧酸盐，所观察到的乳腺癌，肺癌，和CNS癌细胞系的生长抑制米-nitrophenylalkyl碘化物，和p -苯基-取代的细长乙酯，即p -nitrophenylpentanoate和p

  DOI：

  10.1021/jm101182s

文献信息

• Stereoselective organocatalytic oxidation of alcohols to enals: a homologation method to prepare polyenes
  作者：Xiaobei Chen、Yinan Zhang、Huixin Wan、Wei Wang、Shilei Zhang

  DOI：10.1039/c5cc10093c

  日期：——

  A novel organocatalytic oxidation through oxidative enamine catalysis was developed with excellent compatibility for the direct syntheses of enals from simple saturated alcohols. By using this amine-catalyzed IBX-oxidation, a wide...

  开发了一种新型的通过氧化烯胺催化的有机催化氧化方法，该方法与由简单的饱和醇直接合成烯类具有优异的相容性。通过使用这种胺催化的IBX氧化，广泛的...
• VLA-4 inhibitor compounds
  申请人：Daiichi Pharmaceutical Co., LTD.

  公开号：US20030078249A1

  公开（公告）日：2003-04-24

  Compounds that selectively inhibit the binding of ligands to &agr;4&bgr;1 integrin (VLA-4) and methods for their preparation are disclosed. In one embodiment, compounds of the invention are represented by Formula I: 1 As selective inhibitors of VLA-4 mediated cell adhesion, compounds of the present invention are useful in the treatment of conditions associated with such adhesion, including, but not limited to, such conditions as inflammatory and autoimmune responses, diabetes, asthma, psoriasis, inflammatory bowel disease, transplantation rejection, and tumor metastasis. Also disclosed are pharmaceutical compositions, methods of inhibiting VLA-4 mediated cell adhesion and methods of treating conditions associated with LA-4 mediated cell adhesion, which involve compounds of Formula I.

  本发明公开了选择性抑制配体与α4β1整合素（VLA-4）结合的化合物及其制备方法。在一个实施例中，本发明的化合物由式I表示： 1 作为VLA-4介导的细胞粘附的选择性抑制剂，本发明的化合物可用于治疗与该粘附相关的疾病，包括但不限于炎症和自身免疫反应、糖尿病、哮喘、银屑病、炎症性肠病、移植排斥和肿瘤转移。还公开了包含式I化合物的药物组合物、抑制VLA-4介导的细胞粘附的方法以及治疗与VLA-4介导的细胞粘附相关疾病的方法。
• 4-Alkyloxyimino Derivatives of Uridine-5′-triphosphate: Distal Modification of Potent Agonists as a Strategy for Molecular Probes of P2Y₂, P2Y₄, and P2Y₆ Receptors
  作者：P. Suresh Jayasekara、Matthew O. Barrett、Christopher B. Ball、Kyle A. Brown、Eva Hammes、Ramachandran Balasubramanian、T. Kendall Harden、Kenneth A. Jacobson

  DOI：10.1021/jm500367e

  日期：2014.5.8

  Extended N4-(3-arylpropyl)oxy derivatives of uridine-5′-triphosphate were synthesized and potently stimulated phospholipase C stimulation in astrocytoma cells expressing G protein-coupled human (h) P2Y receptors (P2YRs) activated by UTP (P2Y2/4R) or UDP (P2Y6R). The potent P2Y4R-selective N4-(3-phenylpropyl)oxy agonist was phenyl ring-substituted or replaced with terminal heterocyclic or naphthyl rings

  合成了尿苷-5'-三磷酸的扩展N 4 -（3-芳基丙基）氧基衍生物，并在星形细胞瘤细胞中有效刺激磷脂酶 C 刺激，该细胞表达 G 蛋白偶联的人 (h) P2Y 受体 (P2YRs)，由 UTP (P2Y 2/ 4 R) 或 UDP (P2Y 6 R)。有效的 P2Y 4 R-选择性N 4 -(3-苯基丙基)氧基激动剂被苯环取代或被末端杂环或萘基环取代，同时保留了 P2YR 效力。对于两个核碱基均被取代的二核苷四磷酸激动剂，未观察到对远端区域空间位阻的这种广泛耐受性。有效的N 4 -(3-(4-甲氧基苯基)-丙基)氧基类似物19 (EC 50 : P2Y 2 R, 47 nM; P2Y 4 R, 23 nM) 被功能化用于链延伸，使用荧光团的点击束缚作为辅基。的BODIPY 630/650缀合物28（MRS4162）显示出EC 50个的70值，66，和23 nM的在hP2Y 2/4/6分别Rs时，和特异性标记细胞中表达P2Y
• MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS
  申请人：Combs Andrew Paul

  公开号：US20100190804A1

  公开（公告）日：2010-07-29

  The present invention relates to macrocyclic compounds of Formula I: or pharmaceutically acceptable salts thereof or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are JAK/ALK inhibitors useful in the treatment of JAK/ALK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

  本发明涉及以下式I的大环化合物：或其药用可接受的盐或季铵盐，其中所述成员组分在此提供，并且它们的组合物和使用方法，这些JAK/ALK抑制剂在治疗JAK/ALK相关疾病中有用，包括例如炎症和自身免疫性疾病，以及癌症。
• Biocatalytic reduction of α,β-unsaturated carboxylic acids to allylic alcohols
  作者：Godwin A. Aleku、George W. Roberts、David Leys

  DOI：10.1039/d0gc00867b

  日期：——

  enable reduction of α,β-unsaturated carboxylic acids to allylic alcohols and their saturated analogues. These compounds are prevalent scaffolds in many industrial chemicals and pharmaceuticals. A substrate profiling study of a carboxylic acid reductase (CAR) investigating unexplored substrate space, such as benzo-fused (hetero)aromatic carboxylic acids and α,β-unsaturated carboxylic acids, revealed broad

  我们已经开发了强大的体内和体外生物催化系统，能够将α，β-不饱和羧酸还原为烯丙基醇及其饱和类似物。这些化合物是许多工业化学品和制药中的普遍支架。对羧酸还原酶（CAR）的底物谱研究研究未开发的底物空间，例如苯并稠合的（杂）芳族羧酸和α，β-不饱和羧酸，揭示了广泛的底物耐受性，并提供了有关这些底物的反应模式的信息基材。大肠杆菌表达异源CAR的细胞被用作多步氢化催化剂，以将多种α，β-不饱和羧酸转化为相应的饱和伯醇，转化率高达99％以上。大肠杆菌内源性乙醇脱氢酶（ADH）的广泛底物范围以及大肠杆菌细胞出乎意料的C C键还原活性支持了这一点。另外，重组的大肠杆菌细胞将各种苯并稠合的（杂）芳族羧酸转化为相应的伯醇。另一种单罐体外由CAR和葡萄糖脱氢酶（GDH）组成的两酶系统显示了GDH对各种不饱和醛的混杂羰基还原酶活性。因此，将CAR与GDH驱动的NADP（H）回收系统耦合，可从母体羧酸盐中获得多种